<DOC>
	<DOCNO>NCT00124657</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Erlotinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It may also make tumor cell sensitive radiation therapy . Giving radiation therapy together erlotinib may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose erlotinib give together radiation therapy see well work treat young patient newly diagnose glioma .</brief_summary>
	<brief_title>Erlotinib Radiation Therapy Treating Young Patients With Newly Diagnosed Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxicity erlotinib administer radiotherapy young patient newly diagnose high-grade glioma unfavorable low-grade glioma . - Determine 1- 2-year progression-free survival patient treat regimen . Secondary - Determine toxic effect regimen patient . - Correlate genetic abnormality epidermal growth factor receptor ( EGFR ) component downstream pathway treatment response patient treat regimen . - Determine ability erlotinib inhibit EGFR signal patient high-grade glioma require second surgery . - Determine pharmacokinetics erlotinib metabolites patient . - Correlate plasma cerebrospinal fluid level vascular endothelial growth factor basic fibroblast growth factor tumor response patient treat regimen . - Correlate irradiation dosimetry pattern failure , standard investigational imaging , toxicity patient treated regimen . OUTLINE : This phase I dose-escalation study erlotinib follow phase II study . - Phase I : Patients undergo radiotherapy daily , 5 day week , approximately 6½ week . Beginning first day radiotherapy , patient receive oral erlotinib daily 2 year . Cohorts patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . - Phase II : Patients receive erlotinib phase I MTD undergo radiotherapy phase I . PROJECTED ACCRUAL : A total 75-80 patient ( 15-20 phase I portion 60 phase II portion ) accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis highgrade glioma 1 follow type : Unfavorable lowgrade glioma Gliomatosis cerebri bithalamic involvement Histologically confirm highgrade glioma ( WHO grade III IV ) 1 follow subtypes : Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic oligoastrocytoma Anaplastic ganglioglioma Pleomorphic xanthoastrocytoma anaplastic feature Malignant glioneuronal tumor Glioblastoma multiforme Gliosarcoma Newly diagnose disease Intracranial spinal cord tumor allow PATIENT CHARACTERISTICS : Age 3 21 Performance status Karnofsky 40100 % ( age 17 21 year ) OR Lansky 40100 % ( age 3 16 year ) Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Hemoglobin ≥ 8 g/dL ( transfusion allow ) Hepatic Bilirubin &lt; 1.5 time upper limit normal ( ULN ) SGPT &lt; 5 time ULN Albumin ≥ 2 g/dL Renal Creatinine &lt; 2 time normal OR Glomerular filtration rate &gt; 70 mL/min Cardiovascular No significant cardiovascular problem Pulmonary No significant pulmonary problem Other Not pregnant nursing Fertile patient must use effective contraception No uncontrolled infection No significant medical illness PRIOR CONCURRENT THERAPY : Biologic therapy No prior concurrent biologic agent Chemotherapy No prior concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery No 42 day since prior surgery Other No prior concurrent anticancer experimental treatment</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>childhood mixed glioma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood spinal cord neoplasm</keyword>
</DOC>